Truist analyst Karina Rabayeva initiated coverage of Immunome (IMNM) with a Buy rating and $36 price target The company’s lead asset, varegacestat, could deliver superior efficacy with a more convenient dosing regimen compared to the currently approved Ogsiveo in desmoid tumors, the analyst tells investors in a research note. Truist adds that its sees meaningful upside from the upcoming data readout and additional potential from the IM-1021, ROR1 ADC program expected next year.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM:
- Immunome price target raised to $33 from $25 at Stephens
- Immunome’s Strategic Clinical Advancements and Financial Alignment Justify Buy Rating
- Immunome, Inc. Reports Q3 2025 Financial Results
- Immunome’s Strategic Advances and Promising Pipeline Justify Buy Rating
- Immunome reports Q3 EPS (65c), consensus (54c)